Caricamento...

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome

BACKGROUND: Approximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk disease. Some of these patients will initially respond to treatment with growth factors to improve anemia but will eventually cease to respond, while others will be resistant to growth factor th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Galili, Naomi, Tamayo, Pablo, Botvinnik, Olga B, Mesirov, Jill P, Brooks, Margarita R, Brown, Gail, Raza, Azra
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2012
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3407785/
https://ncbi.nlm.nih.gov/pubmed/22559819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-5-20
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !